EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?

Amrit Paudel, Priya Chattopadhyay, Brandon Rose, Aleksandra Watson iD, Gina D'Amato iD, Jonathan Trent iD, Steven Bialick iD, Emily Jonczak

Cancers · 05.03.2025 · 17 (5) · 889

DOI: 10.3390/cancers17050889 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.03.2025. Verfasst von Amrit Paudel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Soft tissue sarcomas [STSs] are rare tumors of mesodermal origin that arise in diverse tissues such as muscles, fat, and nerves. There are over 100 subtypes of STS, each with distinct clinical behaviors and responses to treatment. Recent advances in treatment have moved towards histology-specific approaches, emphasizing the integration of pathological, immunohistochemical, and molecular features to guide treatment. Localized STS is primarily treated with surgery, often supplemented by neoadjuvant or adjuvant radiation and/or chemotherapy. However, about half of patients with localized disease will progress to an advanced stage, which is typically managed with systemic therapies including anthracycline-based chemotherapy such as doxorubicin or epirubicin. Despite these treatments, the survival rates for most subtypes of advanced metastatic STS remain relatively low. While anthracycline-based chemotherapy remains the mainstay of treatment, ongoing research into the biology of STSs is enhancing our understanding and approach to these complex tumors with an expansion beyond chemotherapy to include targeted therapy and immunotherapy to improve response rates and survival outcomes. This review focuses on STS other than gastrointestinal stromal tumors [GISTs], examines the current systemic treatment strategies, highlights recent advances, and explores future directions in the systemic therapy of sarcoma patients.

Schlagwörter

Stichwörter der Autor:innen

anthracyclineschemotherapyimmunotherapysoft tissue sarcomatyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.
  • Department of Internal Medicine, Jackson Health System, University of Miami, Miami, FL 33136, USA.

ORCID-Profile: Aleksandra Watson, Gina D'Amato, Jonathan Trent, Steven Bialick

Zitieren

APA

Paudel, A., Chattopadhyay, P., Rose, B., Watson, A., D'Amato, G., Trent, J., Bialick, S., & Jonczak, E. (2025). Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?. Cancers, 17(5), 889. https://doi.org/10.3390/cancers17050889

Vancouver

Paudel A, Chattopadhyay P, Rose B, Watson A, D'Amato G, Trent J, et al. Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?. Cancers. 2025;17(5):889. doi:10.3390/cancers17050889

BibTeX
@article{Paudel2025,
  author = {Paudel, Amrit and Chattopadhyay, Priya and Rose, Brandon and Watson, Aleksandra and D'Amato, Gina and Trent, Jonathan and Bialick, Steven and Jonczak, Emily},
  title = {Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {5},
  pages = {889},
  doi = {10.3390/cancers17050889}
}
Kostenlos starten →